Novo increases fatty liver efforts: "We've seen some highly convincing data"

Pharmaceutical company Novo Nordisk expands its emphasis on the fatty liver disease NASH. There's a huge market, but no one has solved the puzzle yet.

Novo Nordisk Executive Vice President, Development Martin Holst Lange | Photo: Novo Nordisk / PR

Danish pharmaceutical company Novo Nordisk keeps powering ahead in its efforts to find the first drug in the world which can treat the serious fatty liver disease non-alcoholic steatohepatitis (NASH).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs